Regeneron Pharmaceuticals is among the new investors, as the bioinformatics company continues to scale up its multiomics platform to meet growing demand.
A team compared expression in duodenum samples from active celiac cases, cases in remission, and unaffected controls, identifying active disease-related expression shifts.
The project dovetails with a separate effort to sequence the whole exomes of the samples, the first 50,000 of which became available to researchers this month.
Using exomes and linked electronic health records, the team uncovered a loss-of-function variant associated with decreased risk of liver disease and cirrhosis.
